Screener
Alnylam Pharmaceuticals ALNY Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Alnylam Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The source filing: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 8:11 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001178670-26-000062
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $108,016 | $115,721 |
| Accrued expenses | 1,095,980 | 1,080,197 |
| Operating lease liabilities | 45,933 | 45,518 |
| Deferred revenue | 4,014 | 4,845 |
| Liabilities related to the sale of future royalties and development funding | 258,570 | 220,068 |
| Total current liabilities | 1,512,513 | 1,466,349 |
Cover / Front Matter
FAQ
- What is Alnylam Pharmaceuticals's accrued expenses?
- Alnylam Pharmaceuticals (ALNY) reported accrued expenses of $1.1B in Q2 2026.
- How has Alnylam Pharmaceuticals's accrued expenses changed year-over-year?
- Alnylam Pharmaceuticals's accrued expenses increased by 19.3% year-over-year, from $918.97M to $1.1B.
- What is the long-term trend for Alnylam Pharmaceuticals's accrued expenses?
- Over 5 years (2020 to 2025), Alnylam Pharmaceuticals's accrued expenses has grown at a 24.9% compound annual growth rate (CAGR), from $355.91M to $1.08B.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Alnylam Pharmaceuticals's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude